The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab ... patients whose tumours have high PD-L1 expression brings the drug into competition with Merck & Co’s Keytruda (pembrolizumab), which ...

Encouraging clinical trial results supporting Libtayo's effectiveness ... oEmerging trends influencing market dynamics: Advancements in drug formulations catering to outpatient care.

The approval of Libtayo (cemiplimab) in advanced NSCLC is for first-line treatment of patients with 50% or more PD-L1 expression and no EGFR, ALK or ROS1 aberrations, taking the drug into a large ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

Deborah S. Sarnoff, M.D., talks about the recent breakthrough treatments that are paving the way to treat patients with ...

Libtayo saw global sales jump 50% to $367 million ... due to its strong track record in drug development, successful existing products, and promising pipeline. This was despite the upcoming ...

Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc.

Arm 1 will administer Libtayo on day 5. The Company plans to ... a Phase 2 Clinical Trial THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed ...